Stuart Therapeutics announces issuance of patent covering ophthalmic anterior segment disorders

Stuart Therapeutics Inc. has announced that the United States Patent and Trademark Office (USPTO) has issued a U.S. patent with granted claims for compositions of matter and methods of use in a variety of anterior segment indications in ophthalmology.

According to a news release, Stuart now controls a total of 10 granted patents, including 5 in the United States, with an additional 32 patents currently pending in the US and other countries.

The company noted in its release patents support a growing body of intellectual property supporting the PolyCol platform of Collagen Mimetic Peptide (CMP) therapeutic compounds. This family of peptides is designed to mimic natural collagen fragments, and certain of these peptides have been shown in both pre-clinical testing and clinical trial settings to provide an improvement in diseased and damaged tissues, including those tissues comprising epithelial cells and neuronal cells.

Moreover, the company pointed out the CMP mechanism of action repairs disease damaged structural and extracellular matrix collagen, acting to restore homeostatic cell signaling, improving the cellular microenvironment and reducing inflammation.

The company noted in its news release it controls the rights to this technology for human therapeutic use in ophthalmology through a prior agreement with the patent owner, Sustain Holdings, LLC.

According to the company, those newly granted patent claims expand its intellectual property in ophthalmic anterior segment diseases and disorders. Stuart is currently developing PolyCol sequences for dry eye disease (entering Phase 3 clinical trials in 4Q, 2023), glaucoma, retinal diseases and disorders, and myopia.